TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1576624
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK (250‐mg capsule QID or 20 mg/kg/day suspension)
Study: 24837447
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose sildenafil (25 mg)
Study: 21215143
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose loading alone
Study: 21215143
Drug: Oral standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral standardized fat loading alone
Study: 9584554
Drug: Vanceril treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanceril treatment
Study: 2229497
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (1.5 x 10(6) IU) injected three times weekly for 3 weeks (cumulative dose of 13.5 million IU)
Study: 2229497
Drug: Placebo injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected three times weekly for 3 weeks
Study: 369645
Drug: Endolymphatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endolymphatic therapy
Study: 30274756
Drug: Intra-articular hip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hip injection (IAHI)
Study: 25727055
Drug: Dialogical Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialogical Exposure Therapy
Study: 22368260
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing actinidine (sucked three times a day for six days)
Study: 22368260
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets without actinidine
Study: 15739120
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 30‐45 mg/day
Study: 15739120
Drug: Pioglitazone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone + Metformin (PIO+MET)
Study: 15739120
Drug: Gliclazide (GLIC)
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (GLIC) 80‐320 mg/day
Study: 15739120
Drug: Gliclazide +
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide + Metformin (GLIC+MET)
Study: 9701155
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Zn
Study: 9701155
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Zn
Study: 7832079
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg once daily, SID group)
Study: 7832079
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg in three divided doses, TID group)
Study: 3049876
Drug: Pentoxifylline (Trental)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (Trental) 1200 mg daily (400 mg t.i.d.)
Study: 29362960
Drug: Combination Exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Exercise (CE)
Study: 27442397
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (1000 ml)
Study: 18574578
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo injection (Group II)
Study: 16861942
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tac/MMF/steroids)
Study: 11076430
Drug: Timolol gel
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol gel 0.5% once daily
Study: 11076430
Drug: Timolol aqueous
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol aqueous solution 0.5% twice daily
Study: 9170340
Drug: N-monomethyl-L-arginine (L-NMMA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of NO-synthase
Study: 9170340
Drug: N-monomethyl-L-arginine (L-NMMA)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-monomethyl-L-arginine (L-NMMA)
Study: 8067787
Drug: Rice based
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice based oral rehydration therapy (ORT)
Study: 3287975
Drug: Cefotetan (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (single 2 g dose)
Study: 3287975
Drug: Cefoxitin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (multiple 2 g doses)
Study: 22474419
Drug: Add-on basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on basal insulin therapy on top of oral agents
Study: 16086921
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose before IRA stenting followed by 75 mg daily)
Study: 16086921
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg before IRA stenting followed by 250 mg twice daily)
Study: 17471790
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (14 mg)
Study: 12126990
Drug: Nicotine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7 mg)
Study: 10102963
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate 240 mg b.d. plus furazolidone 100 mg b.d. plus clarithromycin 250 mg b.d. (Group A)
Study: 10102963
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg b.d. plus amoxycillin 1000 mg b.d. (Group B)
Study: 10102963
Drug: Furazolidone 100
Normalized name: furazolidone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone 100 mg b.d. plus josamycin 1000 mg b.d. (Group C)
Study: 2572793
Drug: NG monomethyl‐L‐arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG monomethyl‐L‐arginine (L‐NMMA) infusion into the brachial arteries
Study: 8872666
Drug: Acetylcholine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine infusion
Study: 2572793
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate infusion
Study: 1089474
Drug: Four different
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four different drug combinations
Study: 25421981
Drug: Intensified pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified pharmacological treatment
Study: 22093417
Drug: Aripiprazole (5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5-25 mg/d)
Study: 22093417
Drug: Tiapride (100-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (100-500 mg/d)
Study: 17005086
Drug: Yiweining (YWN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiweining (YWN) 200 ml, twice a day for 6 months
Study: 17005086
Drug: Gestrinone (GT)
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone (GT) 2.5 mg, twice every week for 6 months
Study: 12775135
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 microg, once daily (FP200QD)
Study: 12775135
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg, once daily (MON10QD)
Study: 9185464
Drug: Diltiazem (1‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (1‐3 mcg.kg‐1.min‐1)
Study: 3803417
Drug: Acipimox, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox, 250 mg three times daily
Study: 31541431
Drug: Venetoclax (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (single doses of 10–500 mg or two cycles of 30–600 mg or placebo once daily for 7 days followed by a 21-day washout)
Study: 31541431
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing with lower doses of venetoclax (e.g., 150 mg daily)
Study: 31541431
Drug: Cyclic dosing
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic dosing with higher doses (e.g., 400 mg 1 week on/3 weeks off)
Study: 29752954
Drug: Complete fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete fasting with placebo treatment
Study: 29752954
Drug: Leptin treatment
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin treatment vs placebo
Study: 29752954
Drug: Leptin treatment
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin treatment in women with HA
Study: 27254034
Drug: YF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: YF vaccine with CYD‐TDV
Study: 27254034
Drug: YF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: YF vaccine with placebo
Study: 27254034
Drug: CYD‐TDV after
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD‐TDV after 2 injections
Study: 27254034
Drug: CYD‐TDV after
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD‐TDV after 2 injections (placebo group)
Study: 25083606
Drug: Confocal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confocal laser endomicroscopy (CLE) with food antigens administered directly to the duodenal mucosa.
Study: 17891480
Drug: 250‐mg caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250‐mg caffeine
Study: 17891480
Drug: 200‐mg theanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg theanine
Study: 16025736
Drug: Benidipine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine 4 mg
Study: 8708496
Drug: Oral electrolyte
Normalized name: Hydralyte Oral Electrolyte Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral electrolyte solution made with rice syrup solids
Study: 8708496
Drug: Comparable glucose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparable glucose-based solution
Study: 1874580
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily - morning and 19h30
Study: 1874580
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily - morning and 22h30
Study: 1874580
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once daily at 19h30
Study: 1874580
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once daily at 22h30
Study: 31306495
Drug: Dupilumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks)
Study: 28774488
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution (crystalloid)
Study: 20676755
Drug: Recent aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent aspirin use
Study: 17462588
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy methods focusing on childhood memories
Study: 17462588
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy methods focusing on the present
Study: 11338045
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant chemotherapy (Control)
Study: 10423597
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg/d)
Study: 10423597
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg twice a day)
Study: 7515382
Drug: Xylometazoline 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylometazoline 0.1% vasoconstrictor nasal spray
Study: 20339969
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg daily for 4 weeks)
Study: 17629923
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (SFC) 50/100 mug twice daily
Study: 17629923
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 mug twice daily
Study: 15668601
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein containing 52 mg genistein, 41 mg daidzein, and 6 mg glycitein daily for 1 year
Study: 15668601
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (placebo) daily for 1 year
Study: 12029552
Drug: Iodine-131 iodide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-131 iodide (120 MBq) as diagnostic agent, followed by ablation activity of 131I iodide (4,000 MBq) administered 3-38 days later.
Study: 12029552
Drug: Iodine-123 iodide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-123 iodide (200 MBq) as diagnostic agent, followed by ablation activity administered 5-47 days later.
Study: 7492128
Drug: Colchicine, 0.5
Normalized name: Colchicine, 0.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine, 0.5 mg twice daily
Study: 394315
Drug: Oral streptokinase/streptodornase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral streptokinase/streptodornase
Study: 26014294
Drug: Bevacizumab (B)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (B) 15 mg/kg intravenously plus Carboplatin (CP) and Paclitaxel (CP)
Study: 23907665
Drug: GSK1322322 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 (oral or intravenous administration)
Study: 23907665
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of GSK1322322 (1,000 and 1,500 mg)
Study: 23907665
Drug: Repeat IV
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat IV doses of GSK1322322 (500 to 1,500 mg twice daily)
Study: 23907665
Drug: Supratherapeutic single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic single IV doses of GSK1322322 (2,000 and 3,000 mg)
Study: 20717049
Drug: Bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.25 mg in 0.05 mL) injected around the valve body after surgery
Study: 20717049
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.4 mg/mL for 3 min) applied before valve implantation
Study: 19086709
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 to 100 mg)
Study: 7593877
Drug: Maternal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal treatment investment
Study: 2199847
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (Botox) injections
Study: 2199847
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (Botox) injections (higher dose during open phase)
Study: 28898378
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n=8506)
Study: 28898378
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE, 0.625 mg/d) alone (n=5310)
Study: 28898378
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (CEE+MPA or CEE)
Study: 24212847
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (hypotensive eyedrops)
Study: 22013796
Drug: Wangbi Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wangbi Tablet (WT)
Study: 22013796
Drug: WT +
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: WT + Votalin Tablet
Study: 22013796
Drug: Votalin Tablet
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Votalin Tablet
Study: 7669459
Drug: Oral naproxen
Normalized name: naproxen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naproxen 1 g
Study: 2040354
Drug: Porcine surfactant
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine surfactant (Curosurf, 200 mg/kg body weight)
Study: 7044788
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg orgotein (intra-articular injections, 4 weekly)
Study: 7044788
Drug: Saline (intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (intra-articular injections, 4 weekly)
Study: 31559433
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (3000 IU daily for 26 weeks)
Study: 21902692
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg clopidogrel
Study: 7979499
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (enteral nutrition or corticosteroids)
Study: 20460239
Drug: Fortified soymilk
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified soymilk (20 mL with 185 kBq of 45Ca in 44 mg of calcium carrier)
Study: 17570262
Drug: Medium-chain triglyceride
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-chain triglyceride (MCT), 18 g/d for 90 days
Study: 16034259
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml syringe training aid
Study: 6996107
Drug: Propoxyphene hydrochloride
Normalized name: Propoxyphene Hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propoxyphene hydrochloride (64 mg)
Study: 30106311
Drug: Emulsified cod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsified cod liver oil formulation
Study: 27236884
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with medicine (ACM) - electro-acupuncture combined with injection of dexmedetomidine
Study: 27236884
Drug: Conventional analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesia - injection of dexmedetomidine
Study: 24872682
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (compression therapy and surgery)
Study: 22772512
Drug: Haloperidol-propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol-propofol infusion
Study: 22772512
Drug: Midazolam-propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midazolam-propofol infusion
Study: 11978287
Drug: Isotretinoin at
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin at 0.5 mg/kg per day for 6 months
Study: 10760294
Drug: DHEA, 50
Normalized name: DHEA, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA, 50 mg, orally, daily for a year
Study: 8933125
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 g oil per day for 15 weeks)
Study: 8933125
Drug: DHA-rich oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich oil (4 g oil per day for 15 weeks)
Study: 1434268
Drug: Oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prostaglandin E1 (limaprost)
Study: 30690085
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy regimens (41 identified)
Study: 27328311
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention (oral supplementation)
Study: 24738467
Drug: Shuganyiyang Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuganyiyang Capsules
Study: 24738467
Drug: Tadalafil +
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil + Shuganyiyang Capsules
Study: 31008751
Drug: Dexmedetomidine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (all doses)
Study: 31671191
Drug: Durvalumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab and chemotherapy (high PD-L1 expression)
Study: 31671191
Drug: Durvalumab, tremelimumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab, tremelimumab, and chemotherapy (low PD-L1 expression)
Study: 17370714
Drug: Dietary restriction
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary restriction and physical activity with behaviour therapy
Study: 17370714
Drug: Anti-obesity drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-obesity drugs
Study: 17370714
Drug: Treatment programmes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment programmes
Study: 11120972
Drug: Concentration-controlled therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration-controlled therapy (11 subjects)
Study: 11120972
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (13 subjects)
Study: 26493461
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise programme delivered through a tablet computer, 2 hours of exercises per week for 2 years.